A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.
Abu Dhabi, UAE: Sheikh Shakhbout Medical City (SSMC), one of the UAE’s largest hospitals for serious and complex care and a ...
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback